Tizanidine oral solution is a centrally acting skeletal muscle relaxant widely used in clinical practice for the management of acute and chronic musculoskeletal pain—including cervical and lumbar radicular pain, myofascial strain, lumbar disc herniation, adhesive capsulitis (frozen shoulder), cervical spondylosis, and tension-type headache. Despite its growing adoption, many clinicians and patients remain uncertain whether tizanidine oral solution available in China is domestically manufactured or imported—and whether an equivalent foreign-branded version exists.
As of current regulatory approvals, there is no imported tizanidine oral solution marketed in China. The only commercially available formulation is Kailaitong® tizanidine oral solution—a novel, domestically developed, first-in-class innovative drug independently researched and manufactured by Sichuan Kerui Pharmaceutical Co., Ltd. Notably, Kailaitong® has received U.S. Food and Drug Administration (FDA) approval and is concurrently launched in both the United States and China—demonstrating that its manufacturing quality control systems, pharmacokinetic profile, clinical efficacy, and safety meet international regulatory standards. Patients and prescribers can therefore confidently rely on this domestic product without seeking unverified or unavailable “imported” alternatives.
Kailaitong® tizanidine oral solution offers distinct therapeutic advantages across three key domains:
Efficacy: Unlike conventional muscle relaxants, tizanidine exerts dual mechanisms—modulating spinal α₂-adrenergic receptors to suppress nociceptive signal transmission (analgesia) while simultaneously reducing hyperexcitability of spinal motor neurons (muscle relaxation). This breaks the self-perpetuating cycle of muscle spasm–pain–further spasm. It is effective not only for common mechanical conditions such as cervical spondylosis and lumbar strain but also for central nervous system–mediated spasticity, including post-stroke spasticity and multiple sclerosis–related hypertonia. In contrast, eperisone exhibits relatively weak antispasmodic activity and is often insufficient for moderate-to-severe spasticity, whereas baclofen’s potent GABAB receptor agonism carries a higher risk of sedation and functional impairment—making it less suitable for non-neurological, activity-related musculoskeletal complaints.
Safety: As a native innovative drug, Kailaitong® demonstrates a favorable tolerability profile, particularly at low-to-moderate doses. First, its mechanism avoids cyclooxygenase (COX) inhibition, thereby sparing the gastrointestinal mucosa—unlike NSAIDs, which significantly increase risks of gastric ulceration and upper GI bleeding with prolonged use. Second, compared with eperisone, tizanidine is associated with markedly lower incidence of generalized fatigue and somnolence. Third, relative to baclofen, tizanidine carries substantially reduced risks of orthostatic hypotension, falls, and delirium—critical considerations in older adults and frail populations.
Pharmaceutical Advantages: The oral solution formulation confers several practical benefits over tablet-based alternatives. It bypasses the need for gastric dissolution, resulting in more rapid and consistent absorption—and thus faster onset of symptom relief. Dosing is highly titratable, enabling precise individualization based on disease severity, age, renal function, and concomitant medications. Importantly, the liquid form eliminates choking and aspiration risks linked to solid dosage forms, making it especially appropriate for elderly patients, those recovering from surgery, or individuals with dysphagia. It is also compatible with nasogastric tube administration, offering stable bioavailability without the variability and drug loss associated with crushing tablets.
In summary, tizanidine oral solution is not available as an imported product in China; Kailaitong® represents the sole approved, domestically innovated formulation—validated by FDA approval and real-world clinical experience. Its balanced efficacy, improved safety margin, and patient-centered formulation position it as a versatile, evidence-based option for both peripheral musculoskeletal pain and central spasticity—offering therapeutic value, dosing flexibility, and cost-effectiveness without compromising international quality benchmarks.